Cutaneous Vasculitis During Secukinumab Treatment
Secukinumab is an inhibitor of interleukin IL-17A, and is mainly used in the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis. Although rarely, this drug may induce paradoxical reactions, such as cutaneous vasculitis. Worldwide, only four previous cases of vasculitis induced by secukinumab have been reported. We herein report the first case described in Brazil of cutaneous vasculitis due to secukinumab in a patient with peripheral spondyloarthritis who demonstrated good resolution after withdrawal of the drug and initiation of etanercept. Clinicians should be aware of this rare but potentially serious adverse effect of secukinumab.
Carron P, De Craemer AS, Van den Bosch F. Peripheral spondyloarthritis: a neglected entity–state of the art. RMD Open 2020;6:e001136.
Kiltz U, Sfikakis PP, Gaffney K, Sator PG, von Kiedrowski R, Bounas A, et al. Secukinumab use in patients with moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis in real-world setting in Europe: baseline data from SERENA study. Adv Ther 2020;37(6):2865–2883.
van Mens LJJ, van de Sande MGH, Menegatti S, Chen S, Blijdorp ICJ, de Jong HM, et al. Brief report: interleukin-17 blockade with secukinumab in peripheral spondyloarthritis impacts synovial immunopathology without compromising systemic immune responses. Arthritis Rheumatol 2018;70:1994–2002.
Toussirot É, Aubin F. Paradoxical reactions under TNF-? blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open 2016;2:e000239.
Puig L. Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others. Curr Probl Dermatol 2018;53:49–63.
Navarro-Triviño FJ, Sanchez-Parera R, Ruiz-Villaverde R. Secukinumab-induced paradoxical hidradenitis suppurativa. Dermatol Ther 2020;33:e13150.
Munera-Campos M, Ballesca F, Carrascosa JM. Paradoxical reactions to biologic therapy in psoriasis: a review of the literature. Actas Dermosifiliogr 2018;109:791–800.
Chelli C, Loget J, Vanhaecke C, Durlach A, Gagneux-Lemoussu L, Soriano C, et al. Cutaneous vasculitis with gut involvement during secukinumab treatment for psoriatic arthritis. Acta Derm Venereol 2020;100:adv00077.
Dogra S, Bishnoi A, Narang T, Handa S. Secukinumab-induced paradoxical pustular psoriasis. Clin Exp Dermatol 2019;44:72–73.
Barrado-Solís N, Rodrigo-Nicolás B, De la Morena-Barrio I, Pérez-Pastor G, Sanchis-Sánchez C, Tomás-Cabedo G, et al. Report of two cases of Behçet's disease developed during treatment with secukinumab. J Eur Acad Dermatol Venereol 2020 Apr 10. doi: 10.1111/jdv.16454 [Epub ahead of print].
Wollina U, Schönlebe J, Fürll C. Pyoderma gangrenosum induced by secukinumab - a late paradoxical drug reaction. Dermatol Ther 2020;33:e13161.
Costa-Moreira P, Lopes S, Santos AL, Pedrosa AF, Andrade P, Portugal R, et al. Leukocytoclastic vasculitis related to ustekinumab in a Crohn's disease patient: first case report and literature review. J Crohns Colitis 2020;14:274–276.
Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86:242–251.
Saint Marcoux B, De Bandt M. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 2006;73:710–713.
Villani A, De Fata Salvatores G, Nappa P, Megna M, Fabbrocini G, Napolitano M. Cutaneous leucocytoclastic vasculitis during secukinumab treatment. G Ital Dermatol Venereol 2019 Jan 9. doi: 10.23736/S0392-0488.18.06203-X [Epub ahead of print].
Issue: Vol 7 No 10 (view)